Library.

“Human immunodeficiency virus (HIV) is transmitted through the exchange of bodily fluids.”

The statement gets the main idea right but overstates the scope. HIV is transmitted through certain infectious body fluids—especially blood, semen, vaginal and rectal fluids, and breast milk—not through all bodily fluids. Transmission also requires the fluid to reach mucous membranes, damaged tissue, or the bloodstream, so the broad wording needs an important qualifier.

“Human immunodeficiency virus attacks the human immune system.”

HIV is correctly described as attacking the human immune system. Major health authorities and peer-reviewed literature show that it primarily infects and damages CD4+ T cells and other immune components, impairing immune defense. Variation in severity, treatment response, or rare nonprogression does not change that core fact.

“The abbreviation "HIV" stands for "Human Immunodeficiency Virus".”

Authoritative medical and public-health sources consistently define HIV as “Human Immunodeficiency Virus.” There is no credible evidence for an alternative accepted expansion. Any differing online formulations are simply mistakes, not legitimate medical usage.

“The diabetes drug metformin can suppress HIV replication, keep the virus dormant, and enable long-term remission without the need for daily antiretroviral therapy.”

This claim dramatically overstates the evidence. While metformin shows some ability to modulate HIV biology in laboratory and animal studies, no clinical evidence supports the assertion that it can enable long-term remission without daily antiretroviral therapy. Multiple peer-reviewed studies actually show metformin can increase HIV transcription and reactivate latent virus. All human studies tested metformin only as an add-on to ART, not as a replacement. The claim conflates early-stage, preclinical findings with established clinical capability.

“Metformin can keep HIV in a dormant state by blocking the DDIT4 gene.”

This claim is not supported by the available evidence. No peer-reviewed study links metformin's effects on HIV latency specifically to "blocking the DDIT4 gene." The primary literature describes metformin acting through AMPK/mTOR/mitochondrial pathways with mixed antiviral and proviral effects. Critically, DDIT4 is a negative regulator of mTORC1, so blocking it would increase mTOR activity—the opposite direction needed to promote HIV dormancy. The claim appears to stitch together unrelated biological facts into an unsupported causal chain.